Cytokinetics

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of ALS. Cytokinetics holds the exclusive right to develop and commercialize tirasemtiv throughout the world. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure. Cytokinetics is collaborating with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. Amgen holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and Astellas holds an exclusive license worldwide to develop and commercialize CK-2127107. Both licenses are subject to Cytokinetics' specified development and commercialization participation rights.
Company Growth (employees)
Type
Public
HQ
South San Francisco, US
Founded
1997
Size (employees)
127 (est)
Cytokinetics was founded in 1997 and is headquartered in South San Francisco, US

Cytokinetics Office Locations

Cytokinetics has an office in South San Francisco
South San Francisco, US (HQ)
280 E Grand Ave

Cytokinetics Data and Metrics

Cytokinetics Financial Metrics

Cytokinetics's revenue was reported to be $4.2 m in Q1, 2017
USD

Revenue (Q1, 2017)

4.2 m

Net income (Q1, 2017)

(25.9 m)

EBIT (Q1, 2017)

(23.3 m)

Market capitalization (22-Sep-2017)

689.5 m

Cash (31-Mar-2017)

49.4 m
Cytokinetics's current market capitalization is $689.5 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

30.6 m46.9 m28.7 m106.4 m

Revenue growth, %

53%(39%)271%

R&D expense

49.5 m59.9 m

General and administrative expense

15.1 m27.8 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

7.8 m9.4 m4.4 m6.5 m7.9 m8.4 m5.8 m59 m4.2 m

R&D expense

11.7 m11.4 m9 m12.6 m11.6 m13.5 m9.7 m19.3 m19.3 m

General and administrative expense

4.5 m4 m4.4 m4.5 m5.3 m6.8 m7.1 m7.2 m8.1 m

Operating expense total

16.2 m15.4 m13.3 m17.1 m16.8 m20.4 m16.8 m26.6 m27.4 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

20.2 m20.2 m65.1 m66.9 m

Current Assets

79.3 m131.1 m113.1 m158.6 m

PP&E

1.2 m1.6 m1.8 m3.6 m

Total Assets

83.2 m133 m115.2 m170.1 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

12.4 m12.9 m22.5 m24.8 m26 m42.3 m27.7 m30.3 m49.4 m

Current Assets

80.1 m81.5 m110.8 m107.9 m100.5 m106.1 m96.6 m148.2 m211 m

PP&E

1.5 m1.5 m1.6 m1.6 m1.5 m1.8 m1.7 m2 m3.5 m

Total Assets

96.1 m87.2 m122.2 m112.7 m102.2 m113.2 m106.2 m158.2 m265.4 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(33.7 m)(14.6 m)(37.5 m)16.5 m

Accounts Payable

1.7 m(2.2 m)755 k1.7 m

Cash From Operating Activities

(7.7 m)(44.8 m)4.9 m37 m

Purchases of PP&E

(542 k)(1.1 m)(562 k)(1.6 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(8.4 m)(6 m)(8.9 m)(10.6 m)(8.8 m)(12.5 m)(11.6 m)31.9 m(25.9 m)

Accounts Payable

985 k1.6 m1.4 m1.6 m1.9 m547 k2.8 m668 k3 m
USDY, 2017

Revenue/Employee

32.7 k

Financial Leverage

2.8 x
Show all financial metrics

Cytokinetics Market Value History

Cytokinetics Job Categories

Traffic Overview of Cytokinetics

Cytokinetics Online and Social Media Presence

Cytokinetics Company Life and Culture

You may also be interested in